Evolution and viral characteristics of a long-term circulating resistant hiv-1 strain in a cluster of treatment-naive patients

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1246-1250

  Marije Hofstra, L ^a   Nijhuis, Monique ^a   Pingen, Marieke ^a   Mudrikova, Tania ^a   Riezebos Brilman, Annelies ^b   Simoons Smit, Alberdina M ^c   Van Ham, Petra M ^a   Bierman, Wouter F W ^b   Wensing, Annemarie M J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clusters; Drug resistance; Persistence; Transmission

Indexed keywords

RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; EPIDEMIOLOGICAL DATA; FEMALE; GENE MUTATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MALE; MOLECULAR CLONING; NONHUMAN; PHYLOGENY; SEROLOGY; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION;

CLUSTERS; DRUG RESISTANCE; PERSISTENCE; TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLONING, MOLECULAR; DNA, VIRAL; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PHENOTYPE; PHYLOGENY; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84884936853     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt038     Document Type: Article

References (17)

1. Wensing AM, van de Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192: 958-66.
2. Frentz D, van de Vijver DA, Abecasis A et al. Transmission of HIV resistant to non-nucleoside RT inhibitors is rising in MSM in Europe. In: Abstracts of the Thirteenth European AIDS Conference, Belgrade, Serbia, 2011. Abstract PS1/5, p. 11. European AIDS Clinical Society, Brussels, Belgium.
3. Castor D, Low A, Evering T et al. Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr 2012; 61: 1-8.
4. Brenner BG, Roger M, Moisi DD et al. Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 2008; 22: 2509-15.
5. Yerly S, Junier T, Gayet-Ageron A et al. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 2009; 23: 1415-23.
6. Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 1998; 72: 3773-8.
7. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472-80.
8. Pingen M, Nijhuis M, de Bruijn JA et al. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 2011; 66: 1467-80.
9. Brenner BG, Routy JP, Petrella M et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76: 1753-61.
10. Audelin AM, Gerstoft J, Obel N et al. Molecular phylogenetics of transmitted drug resistance in newly diagnosed HIV type 1 individuals in Denmark: a nation-wide study. AIDS Res Hum Retroviruses 2011; 27: 1283-90.
11. Kouyos RD, von Wyl V, Yerly S et al. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 2011; 52: 532-9.
12. Huigen MC, de Graaf L, Eggink D et al. Evolution of a novel 5-amino-acid insertion in the b3-b4 loop of HIV-1 reverse transcriptase. Virology 2007; 364: 395-406.
13. Boucher CA, KeulenW, van Bommel T et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996; 40: 2404-9.
14. Boom R, Sol CJ, Salimans MM et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495-503.
15. Buskin SE, Ellis GM, Pepper GG et al. Transmission cluster of multiclass highly drug-resistant HIV-1 among 9 men who have sex with men in Seattle/King County, WA, 2005-2007. J Acquir Immune Defic Syndr 2008; 49: 205-11.
16. Hue S, Gifford RJ, Dunn D et al. Demonstration of sustained drugresistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 2009; 83: 2645-54.
17. Lindstrom A, Ohlis A, Huigen M et al. HIV-1 transmission cluster with M41L 'singleton' mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men. Antivir Ther 2006; 11: 1031-9.